Results 31 to 40 of about 130,730 (348)

The impact of drug-drug interactions between proton pump inhibitors and metformin: A systematic review of clinical evidence [PDF]

Pharmacia
Metformin, a substrate of the organic cation transporters, is commonly co-prescribed with proton pump inhibitors, which inhibits these transporters. However, the clinical significance of this potential drug-drug interaction remains unclear.
Ria Andani Antong, Ikhwan Yuda Kusuma, Marianti A. Manggau, Muh Akbar Bahar   +3 more
doaj   +3 more sources

Iron deficiency anemia from iron malabsorption caused by proton pump inhibitors

eJHaem, 2020
Background Iron deficiency anemia without evidence for blood loss can present a diagnostic challenge. Proton pump inhibitors have been associated with iron deficiency anemia for many years, yet the relationship between the two until recently was not ...
Michael Boxer
doaj   +1 more source

Esophageal sphincter device for gastroesophageal reflux disease [PDF]

, 2013
BACKGROUND Patients with gastroesophageal reflux disease who have a partial response to proton-pump inhibitors often seek alternative therapy. We evaluated the safety and effectiveness of a new magnetic device to augment the lower esophageal sphincter ...
Bemelman, Willem A, Dunn, Dan, Dunst, Christy M, Edmundowicz, Steven A, Ganz, Robert A, Horgan, Santiago, Lipham, John C, Luketich, James D, Melvin, W. Scott, Oelschlager, Brant K, Peters, Jeffrey H, Schlack-Haerer, Steven C, Smith, C. Daniel, Smith, Christopher C, Taiganides, Paul A   +14 more
core   +2 more sources

Overuse of proton pump inhibitors [PDF]

Polish Archives of Internal Medicine, 2015
Proton pump inhibitors (PPIs) are currently the most effective drugs inhibiting hydrochloric acid secretion. They have replaced histamine type 2 receptor antagonists in the majority of clinical indications, for example, functional dyspepsia, gastroesophageal reflux disease, or drug‑induced upper gastrointestinal tract injury.
Dorota, Ksiądzyna, Adam, Szeląg, Leszek, Paradowski   +2 more
openaire   +2 more sources

Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients [PDF]

, 2016
Purpose: Methotrexate administration is associated with frequent adverse neurological events during treatment for childhood acute lymphoblastic leukemia.
Baird, Susan F., Forster, Victoria J., Halsey, Christina, Mair, Shona, Skinner, Roderick, van Delft, Frederik W.   +5 more
core   +2 more sources

Proton pump inhibitors and the risk of pneumonia: A comparison of cohort and self-controlled case series designs [PDF]

, 2013
Background: To compare the results of a new-user cohort study design and the self-controlled case series (SCCS) design using the risk of hospitalisation for pneumonia in those dispensed proton pump inhibitors compared to those unexposed as a case study ...
Australian Bureau of Statistics (ABS), C Farrington, C Farrington, C-S Eom, CP Farrington, DA Zink, Elizabeth E Roughead, Emmae N Ramsay, HJ Whitaker, HJ Whitaker, J Glanz, J Hippisley-Cox, KL Sloan, L Thomas, Nicole L Pratt, Philip Ryan, R Laheij, RJ Laheij, S Gulmez, S Suissa, S Suissa, SE Gulmez, SV Gadzhanova   +22 more
core   +1 more source

The choice of proton pump inhibitor from the standpoint of efficacy and safety in a particular patient

Лечащий Врач, 2021
Proton pump inhibitors are a diverse class of drugs with unique acid suppression properties. The aim of the work was to present the therapeutic benefits of rabeprazole and pantoprazole in clinical practice.
E. A. Lyalukova, Yu. V. Tereschenko, E. N. Chernysheva, A. V. Lyalukov   +3 more
doaj   +1 more source

Structures and proton-pumping strategies of mitochondrial respiratory enzymes [PDF]

, 2001
Enzymes of the mitochondrial respiratory chain serve as proton pumps, using the energy made available from electron transfer reactions to transport protons across the inner mitochondrial membrane and create an electrochemical gradient used for the ...
Chan, Sunney I., Schultz, Brian E.
core   +1 more source

Proton pump inhibitor-induced Sweet’s syndrome: report of acute febrile neutrophilic dermatosis in a woman with recurrent breast cancer

Dermatology Practical & Conceptual, 2015
Background: Sweet’s syndrome, also referred to as acute febrile neutrophilic dermatosis, can either occur as an idiopathic disorder or associated with another condition, including cancer, or induced by exposure to a drug.
Philip R. Cohen
doaj   +1 more source

Proton pump inhibitors overuse - consequences among patients

Journal of Education, Health and Sport, 2019
Introduction Omeprazole was first proton pump inhibitor (PPI) approved for use by patients. Thirty years have passed since then. Due to their effectiveness, low price and safety proton pump inhibitors have become one of the most frequently prescribed ...
Patrycja Kmiotek, Andrzej Materniak, Barbara Skrzydło-Radomańska   +2 more
doaj   +3 more sources